$100 for a Covid-19 vaccine? That's what Moderna says may be coming
As Moderna pivots away from Covid-19 to other vaccines, the mRNA-focused biotech is still plotting how it could hit $13 billion in annual US Covid-19 vaccine sales, with $100 shots and 50% of all adults getting a booster.
But the Boston-based company’s lofty expectations, revealed in a slide show yesterday as part of its R&D day, included an estimate that the worldwide pandemic Covid-19 vaccines market is worth more than $100 billion globally, as in high-income countries, the eligible high-risk population (elderly and those with high risk) is about 340 million people.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.